ADMA Biologics (ADMA) updated investors with fresh projections through 2027, outlining revenue, adjusted EBITDA and margin expectations that draw directly on yield focused manufacturing changes and a repositioned plasma collection network.

At a share price of $17.95, ADMA Biologics has given investors a 90 day share price return of 20.07%, while the 1 year total shareholder return sits at 8.85%, building on a very large 5 year total shareholder return that is several multiples of the starting value. Recent guidance updates and participation in the J.P. Morgan Healthcare Conference help frame this momentum as investors reassess both growth potential and execution risk around its plasma derived biologics portfolio.

If this kind of healthcare story has your attention, it could be a good moment to broaden your watchlist with other healthcare stocks that may fit your approach.

With shares up 20.07% over 90 days and the price sitting at a steep discount to the average analyst target and an estimated intrinsic value, the key question now is whether ADMA is still mispriced or if the market is already accounting for those ambitious 2027 goals.

Most Popular Narrative: 34.1% Undervalued

Compared with ADMA Biologics' last close at $17.95, the most followed narrative points to a fair value of $27.25, creating a sizeable valuation gap for investors to assess.

Continued progress in the product pipeline including SG-001, which addresses unmet infectious disease needs and could potentially add $300–$500 million in annual revenue, offers significant future earnings upside and diversification of revenue streams.

Curious what kind of revenue ramp, profit margins and valuation multiple are baked into that fair value, and how a single pipeline asset is modeled into the story?

Using a 7.06% discount rate, the narrative ties together high revenue growth assumptions, robust long term profit margins and a higher future P/E multiple to arrive at $27.25 per share.

Those inputs sit alongside expectations for earnings to grow meaningfully over several years, with valuation grounded in where the company might trade once it reaches a higher profit base.

Analysts in that narrative also build in modest share count expansion and keep the discount rate only slightly above prior estimates, which keeps the present value of future earnings relatively high.

At the same time, the current share price sits below both that fair value estimate and the narrative's implied future P/E, leaving readers to decide whether those assumptions feel reasonable enough to close the gap.

Result: Fair Value of $27.25 (UNDERVALUED)

However, that upside story relies heavily on a narrow product lineup and a smooth scale-up of the yield enhancement process, so any regulatory or manufacturing setback could quickly challenge it.

Build Your Own ADMA Biologics Narrative

If you are not convinced by this storyline or prefer to stress test the numbers yourself, you can build a custom view in minutes with Do it your way.

A great starting point for your ADMA Biologics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single company; use the Simply Wall Street Screener to uncover more targeted ideas.

• Target steady income by checking out these 12 dividend stocks with yields > 3% that offer yields above 3% while you assess their fundamentals and payout records.
• Spot the next wave of market leaders by scanning these 26 AI penny stocks that are tied to artificial intelligence themes and related growth stories.
• Hunt for potential value opportunities with these 885 undervalued stocks based on cash flows where current prices differ from estimated cash flow based worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.